Avalo Therapeutics (NASDAQ:AVTX) Given “Buy” Rating at BTIG Research

BTIG Research reiterated their buy rating on shares of Avalo Therapeutics (NASDAQ:AVTX) in a research report released on Monday morning,Benzinga reports. They currently have a $40.00 target price on the stock.

A number of other equities research analysts also recently issued reports on the stock. Guggenheim started coverage on shares of Avalo Therapeutics in a research report on Monday, February 2nd. They set a “buy” rating and a $50.00 price objective for the company. Wolfe Research started coverage on shares of Avalo Therapeutics in a research report on Thursday, April 9th. They issued an “outperform” rating and a $48.00 price target for the company. HC Wainwright upped their price target on shares of Avalo Therapeutics from $25.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, March 25th. Wall Street Zen upgraded shares of Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Sunday, March 29th. Finally, Mizuho upgraded shares of Avalo Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $44.83.

Avalo Therapeutics Price Performance

Shares of AVTX stock opened at $13.34 on Monday. Avalo Therapeutics has a 1 year low of $3.39 and a 1 year high of $20.72. The firm has a fifty day moving average price of $15.44 and a 200-day moving average price of $16.16. The company has a market cap of $304.02 million, a price-to-earnings ratio of -2.33 and a beta of 0.93.

Avalo Therapeutics (NASDAQ:AVTX) last issued its quarterly earnings data on Monday, March 23rd. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.54) by $1.17. The business had revenue of $0.06 million for the quarter, compared to the consensus estimate of ($0.21) million. Equities research analysts expect that Avalo Therapeutics will post -19.07 EPS for the current year.

Insider Buying and Selling

In other news, CFO Christopher Ryan Sullivan sold 7,980 shares of the business’s stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $17.15, for a total value of $136,857.00. Following the transaction, the chief financial officer owned 17,338 shares of the company’s stock, valued at approximately $297,346.70. The trade was a 31.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mittie Doyle sold 25,492 shares of the business’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $16.15, for a total transaction of $411,695.80. Following the completion of the transaction, the insider directly owned 3,622 shares in the company, valued at $58,495.30. This trade represents a 87.56% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 46,100 shares of company stock valued at $764,724. Company insiders own 0.25% of the company’s stock.

Hedge Funds Weigh In On Avalo Therapeutics

Hedge funds have recently modified their holdings of the stock. Patient Square Capital LP purchased a new position in shares of Avalo Therapeutics in the third quarter worth $1,271,000. Cantor Fitzgerald L. P. purchased a new position in shares of Avalo Therapeutics in the third quarter worth $1,083,000. Boothbay Fund Management LLC lifted its holdings in shares of Avalo Therapeutics by 1,916.6% in the third quarter. Boothbay Fund Management LLC now owns 228,297 shares of the company’s stock worth $2,902,000 after buying an additional 216,976 shares in the last quarter. Ally Bridge Group NY LLC purchased a new position in shares of Avalo Therapeutics in the third quarter worth $2,264,000. Finally, Boxer Capital Management LLC purchased a new position in shares of Avalo Therapeutics in the third quarter worth $1,589,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.